Perioperative chemotherapy-immunotherapy with nivolumab "significantly improves" overall 5-year survival against chemotherapy in patients with non-small cell lung cancer (NCLC) - the most common type of this resectable cancer (which can be removed by surgery) stage III. In addition, the complete pathological response (CPR) following neoadjuvant treatment, which is administered prior to surgery, consolidates "as a robust prognostic factor of long…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Perioperative chemotherapy-immunotherapy with nivolumab "significantly improves" overall 5-year survival against chemotherapy in patients with non-small cell lung cancer (NCLC) - the most common type of this resectable cancer (which can be removed by surgery) stage III. In addition, the complete pathological response (CPR) following neoadjuvant treatment, which is administered prior to surgery, consolidates "as a robust prognostic factor of long…